In 2023, the leukemia mortality rate for women in Switzerland stood at 5.9 deaths per hundred thousand women. The forecast from 2024 to 2028 remains constant at 5.9 units, indicating no expected year-on-year variation. This stability suggests an absence of significant advancements or setbacks in the prevention and treatment of leukemia among Swiss women over this period. With no variation observed over the last two years, the Compound Annual Growth Rate (CAGR) is 0% over the last five years.
Future trends to watch for include potential breakthroughs in medical research and treatments that could lower the mortality rate, public health initiatives targeting early detection and prevention, and demographic changes that may impact leukemia incidence and mortality rates.
